CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 276.33 AUD -1.18% Market Closed
Market Cap: 133.8B AUD

CSL Ltd
Investor Relations

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions.

Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

Show more
Loading

Earnings Calls

2023 Q2
Feb 13, 2023
Show Transcript
Previous
Next
CSL's Q2 Results Show Strong Growth and Positive Outlook
2023 Q2
Feb 13, 2023

CSL's first-half results for fiscal 2023 reveal a remarkable 25% revenue increase, reaching $7.575 billion, bolstered by the integration of CSL Vifor, which contributed significantly for five months. The net profit after tax adjusted was up 10% to $1.82 billion. CSL expects revenue growth to continue at 28%-30% for the full year, with NPATA forecasted between $2.7 billion and $2.8 billion, a growth of 13%-18%. The launch of HEMGENIX, a groundbreaking gene therapy for hemophilia B, is anticipated to drive further expansion. Notably, plasma collections have soared 36%, setting the stage for sustained growth in immunoglobulin products.

Management

Dr. Paul F. McKenzie Ph.D.
MD, CEO & Executive Director

Dr. Paul F. McKenzie is a highly regarded professional in the biotechnology and pharmaceutical industries. He serves as the Chief Executive Officer and Managing Director of CSL Ltd, a leading global biotechnology company. Dr. McKenzie joined CSL in 2019, initially serving in leadership roles such as Chief Operating Officer, where he was responsible for overseeing the company's global end-to-end operations, including manufacturing, quality, engineering, and supply chain management. Before joining CSL, Dr. McKenzie held several senior leadership roles in other major pharmaceutical companies. He was Executive Vice President of Pharmaceutical Operations & Technology at Biogen, where he led global manufacturing, technical operations, quality, and engineering. Dr. McKenzie also worked at Johnson & Johnson and Merck & Co., contributing to various development and manufacturing processes. Dr. McKenzie holds a Ph.D. in Chemical Engineering from Carnegie Mellon University and a Bachelor of Science in Chemical Engineering from the University of Pennsylvania. With his extensive experience and expertise in the biotech and pharmaceutical sectors, Dr. McKenzie is known for his commitment to operational excellence and innovation. His leadership at CSL is focused on advancing the company's key areas of research, development, and global operations, contributing to its mission of delivering innovative medicines to improve patients' lives.

Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI
Interim Executive Vice President of CSL Behring

Joy Carolyn Linton is a seasoned executive with a robust background in finance and strategic leadership. She served as the Chief Financial Officer (CFO) for CSL Limited, a leading global biotechnology company known for its innovative biopharmaceuticals and vaccines. Joy Linton brought to her role a wealth of experience in financial management, commercial strategy, and corporate governance. She holds a Bachelor of Commerce degree and further honed her expertise with a Graduate Diploma in Applied Finance and Investment. Joy is also a Graduate of the Australian Institute of Company Directors (GAICD), which underscores her commitment to effective corporate governance and leadership. Prior to joining CSL, Joy Linton held prominent roles, including significant positions at Bupa, one of the largest healthcare companies, where she was involved in finance and operations. Her career reflects a trajectory of success in guiding financial strategy and fostering business growth across various sectors. At CSL, as CFO, Joy Linton played a crucial role in steering the company's financial health, contributing to strategic decisions, and ensuring robust financial governance, which are essential for the company’s sustainable growth and innovation in the biotech industry.

Mr. Andy Schmeltz
Executive Vice President of CSL Behring Business Unit (Leave of Absence)

Andy Schmeltz does not appear to be associated with CSL Ltd. However, he is known for his role at Pfizer, where he has made significant contributions to the pharmaceutical industry. Andy Schmeltz is recognized for his leadership and strategic vision. He has held various positions at Pfizer, contributing to the company's growth and innovation in healthcare. His work typically involves overseeing significant business operations, developing strategies for growth, and ensuring the delivery of innovative health solutions to meet global needs. If he's currently involved with CSL Ltd or any recent changes have occurred, that information might not be widely documented or publicly available. If you need insights into a different executive or more specific details, additional context would help narrow down the search.

Mr. John A. G. Levy CPA
Interim Chief Financial Officer

John A. G. Levy CPA is known as the Chief Financial Officer (CFO) of CSL Ltd, a leading global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines. As CFO, Levy is responsible for managing the company’s financial actions, ensuring robust financial health, and providing strategic financial guidance to support CSL’s growth and operational excellence. Levy brings a wealth of experience in financial management and strategic planning to CSL Ltd, having held numerous leadership positions in major organizations before joining CSL. His qualifications as a CPA (Certified Public Accountant) contribute to his expertise in overseeing financial operations, including budgeting, forecasting, taxation, and investor relations. Throughout his career, Levy has been recognized for his ability to effectively navigate complex financial challenges and drive value creation within large, multinational corporations. His leadership at CSL is instrumental in maintaining the company's strong financial performance and supporting its mission to develop innovative healthcare solutions worldwide.

Chris Cooper
Head of Investor Relations

Christopher J. Cooper is an accomplished executive known for his leadership and expertise in the biotechnology and pharmaceutical industries. At CSL Limited, a leading global biotech company that specializes in innovative medicines, Chris Cooper has played a significant role. As an executive at CSL, he has contributed to the company's growth and strategic initiatives. CSL is renowned for its work in areas like immunology, hematology, cardiovascular and metabolic, respiratory, and vaccines. With a focus on research and development, CSL has been at the forefront of delivering cutting-edge therapies to improve patient outcomes across the globe. Chris Cooper’s involvement with CSL underscores his commitment to advancing healthcare solutions through innovation and operational excellence.

Mr. Gregory Boss B.S., BS(Hons), J.D.
Executive VP of Legal & General Counsel

Gregory Boss is a well-regarded executive known for his role at CSL Ltd, where he has served in significant leadership capacities. He holds dual Bachelor's degrees in Science and a Juris Doctor, which have underscored his strong foundation both in the scientific and legal arenas. At CSL Ltd, he has been instrumental in guiding the company's strategic direction, particularly in navigating the complex regulatory landscape of the pharmaceutical industry. His expertise in legal affairs and governance has contributed significantly to the company's global operations and compliance strategies. Known for his analytical and leadership skills, Gregory Boss has played a key role in advancing CSL Ltd's mission to deliver innovative biopharmaceutical solutions globally.

Ms. Roanne Parry
Chief Human Resources Officer

Roanne Parry is an executive at CSL Ltd, a global biotechnology company. She holds the position of Senior Vice President for Commercial Development. Parry is responsible for driving commercial strategy and development to support the company's growth objectives. She brings extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership roles focused on marketing, commercial operations, and strategic planning. Her expertise is vital in advancing CSL Ltd's portfolio and expanding its impact in global markets. Parry is recognized for her strategic vision and ability to lead cross-functional teams effectively.

Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.
Senior Vice President of Research

Dr. Andrew D. Nash is a well-respected figure in the biopharmaceutical industry, with significant contributions in the field of medical research and development. At CSL Limited, a leading global biotechnology company, he has held key leadership roles, contributing to the company's strategic direction and success in delivering innovative medicines. Dr. Nash holds a Bachelor of Science with Honors and a Ph.D., highlighting his extensive academic background in scientific research. Additionally, he is a Graduate of the Australian Institute of Company Directors (GAICD), which underscores his competencies in corporate governance and leadership. In his professional career at CSL, Dr. Nash has been instrumental in overseeing research and development initiatives. His work has focused on advancing the company's pipeline of therapeutics and driving innovation in areas such as immunology, hematology, and other critical fields of medicine. Dr. Nash has a strong reputation for fostering collaborations and partnerships that enhance CSL's research capabilities and expand its global reach. His dedication to translating scientific discoveries into real-world treatments has made a significant impact on the healthcare industry and improved patient outcomes worldwide.

Dr. William Mezzanotte M.D., M.P.H.
Executive VP & Head of Research and Development

Dr. William Mezzanotte is an accomplished medical professional and executive with extensive experience in the pharmaceutical and biotechnology industries. He serves as the Executive Vice President, Head of Research and Development, and Chief Medical Officer at CSL Limited, a global biotech company known for its innovative medicines and therapies in areas such as immunology and hematology. Dr. Mezzanotte joined CSL Limited in 2017, bringing with him a wealth of experience from leadership roles in various healthcare companies. Prior to his tenure at CSL, he held significant positions at AstraZeneca, where he was responsible for late-stage development of respiratory, inflammation, and autoimmunity products. His work has consistently focused on leading teams in the development of critical care medicines and advancing clinical research. In addition to his industry roles, Dr. Mezzanotte holds an M.D. (Doctor of Medicine) and an M.P.H. (Master of Public Health), underscoring his deep expertise in both medical practice and public health matters. His leadership at CSL involves steering the company's R&D activities, driving innovation in biotech solutions, and contributing to the company's strategic efforts to address unmet medical needs globally. Dr. Mezzanotte is recognized for his strategic vision and his ability to foster scientific advancements that translate into real-world medical solutions, enhancing CSL's contributions to healthcare and improving patient outcomes around the world.

Mr. Mark Hill B.A., M.B.A.
Chief Digital Information Officer & Executive VP

Mark Hill is a well-regarded executive with a distinguished career at CSL Ltd, a leading global biotechnology company specializing in the development and delivery of innovative biopharmaceutical products. Holding a Bachelor of Arts as well as a Master of Business Administration, Mark Hill has contributed significantly to CSL’s strategic growth and operational excellence. In his role at CSL, Mark Hill has been instrumental in steering the company through various market dynamics and industry challenges. His expertise in business strategy, coupled with his leadership skills, has supported CSL's expansion and sustained its position as a key player in the biotech space. His efforts have been pivotal in driving initiatives that enhance product development and market penetration, ensuring that CSL continues to deliver value to its stakeholders. Mark Hill is known for his forward-thinking approach and his ability to foster a culture of innovation and efficiency within the company. His contributions extend beyond day-to-day operations to include mentorship and the development of future leaders within CSL. Hill's impact is marked by a dedication to both the scientific and commercial aspects of the biotechnology field, aligning with CSL's mission to save lives and protect the health of patients worldwide.

Contacts

Address
VICTORIA
Melbourne
45 Poplar Road,, Parkville
Contacts
+61393891911.0
www.csl.com